WallStSmart
PTGX

Protagonist Therapeutics Inc

NASDAQ: PTGX · HEALTHCARE · BIOTECHNOLOGY

$103.50
-5.26% today

Updated 2026-06-05

Market cap
$6.10B
P/E ratio
P/S ratio
85.51x
EPS (TTM)
$-1.81
Dividend yield
52W range
$49 – $108
Volume
0.6M

Protagonist Therapeutics Inc (PTGX) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-282.83%
Operating margin
-343.63%
ROE
-17.50%
ROA
-12.40%
Debt/equity
0.01x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2014$0.00$-11.07M
2015$0.00$-14.86M
2016$0.00$-37.18M
2017$20.06M$-36.96M100.00%-188.89%-184.20%
2018$30.93M$-38.92M100.00%-136.68%-125.87%
2019$231000.00$-77.19M100.00%-34,857.58%-33,414.29%
2020$28.63M$-66.15M100.00%-225.36%-231.07%
2021$27.36M$-125.55M100.00%-460.01%-458.94%
2022$26.58M$-123.41M100.00%-494.24%-464.29%
2023$60.00M$-78.95M100.00%-156.09%-131.59%
2024$434.43M$275.19M100.00%58.20%63.34%
2025$46.02M$-130.15M97.34%-343.63%-282.83%

Frequently asked questions

What is Protagonist Therapeutics Inc's revenue?

Protagonist Therapeutics Inc's trailing twelve-month revenue is $74.06M, and consensus projects about $620.00M by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is PTGX?

In its most recent fiscal year, PTGX ran a gross margin of 97.34%, an operating margin of -343.63%, and a net margin of -282.83%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does PTGX generate?

PTGX produced $56.08M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PTGX's balance sheet healthy?

PTGX holds $128.39M in cash and equivalents against — in long-term debt, on $614.71M of shareholder equity. That debt is best read against the cash flow the business throws off each year.